Liquid Biopsy Global Market – Forecast To 2024

Publishing Date : March, 2018
Report Code : HCMD0157
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Liquid biopsy is process of obtaining non-solid tissue usually the blood and other body fluids (urine, saliva etc.) obtained non-invasively as a diagnosis and monitoring tool for disease such as cancer through identification of biomarker in form of cell-fee DNA or circulating tumor cells (CTC) to advance personalized medicine, and improve the quality of life. The groundbreaking discovery of cfDNA in 1948 has opened up new possibilities in the field of oncology, transplantation and non-invasive prenatal screening.

According to IQ4I analysis, the liquid biopsy global market is projected to reach $8,730.4 million by 2024. The liquid biopsy global market is segmented based on the biomarkers, applications, sample type, end-users and geography.

Biomarkers market is divided into circulating tumor cells (CTC), cell-free DNA and Exosomes & Others, among which, the Cell-free DNA market commanded the largest share. The utilization of circulating tumor cell as an invaluable research tool is expected to propel this market at a strong CAGR.

The applications market is divided into oncology testing, prenatal (NIPT) testing and transplantation diagnostics where oncology testing dominates the application market which is followed by prenatal testing (NIPT), however, the rapid adoption of cfDNA based transplantation diagnostics testing is expected to drive this market at high double digit CAGR.

The oncology testing market is further divided based on type of cancer tested into breast cancer, colorectal cancer, lung cancer, prostate cancer, melanoma, ovarian cancer and others, where, breast cancer commanded largest share in 2017, lung cancer is projected to grow at highest CAGR from 2017 to 2024. The oncology testing market is further divided based on type of cancer care into early screening, companion diagnostics, prognosis and recurrence monitoring. The companion diagnostics monitoring market dominates the market in 2017, while early screening is expected to grow at strong CAGR.

The liquid biopsy sample market is divided into blood, urine and others where blood dominates the market in 2017 and is expected to maintain the position with strong CAGR growth from 2017 to 2024.

The end-users market is segmented into Hospitals and academic and research institutes. Hospitals attracted the largest revenue in 2017. The hospitals segment is expected to show strong CAGR growth from 2017 to 2027.

The liquid biopsy geographical market consists of North America, Europe, Asia-Pacific and RoW, where, North America dominates the market in 2017 followed by Europe with Asia-Pacific market expected to show highest growth from 2017 to 2024.

 The report provides an in depth market analysis of the above mentioned segments across the following regions:

  • North America
  • Europe
  • Asia-Pacific 
  • Rest of the World (RoW)
  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKE AWAYS
    • 2.2     REPORT DESCRIPTION
    • 2.3     MARKETS COVERED
    • 2.4     STAKEHOLDERS
    • 2.5     RESEARCH METHODOLOGY
      • 2.5.1     MARKET SIZE ESTIMATION
      • 2.5.2     MARKET CRACKDOWN AND DATATRIANGULATION
      • 2.5.3     SECONDARY SOURCES
      • 2.5.4     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.5.5     PRIMARY SOURCES
      • 2.5.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.5.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     RISING INCIDENCE OF CANCER
        • 3.3.1.2     INCREASING PREFERENCE FOR BLOOD/URINE BASED LIQUID BIOPSY OVER INVASIVE TISSUE BIOPSY PROCEDURES
        • 3.3.1.3     RISING NUMBER OF LATE PREGNANCIES LEADING TO HIGH INCIDENCE RATE OF BABIES WITH CHROMOSOMAL DISORDERS
        • 3.3.1.4     INCREASING FUNDING FOR LIQUID BASED TEST DEVELOPMENT
        • 3.3.1.5     TECHNOLOGICAL ADVANCEMENTS IN LIQUID BIOPSY
        • 3.3.1.6     AGREEMENTS AND COLLABORATIONS
        • 3.3.1.7     INCREASING NUMBER OF LIQUID BIOPSY TEST LAUNCHES
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     HIGH COST WITH LESS REIMBURSEMENT FACILITIES
        • 3.3.2.2     ETHICAL ISSUES RELATED TO GENETIC TESTING
        • 3.3.2.3     LACK OF SKILLED HEALTHCARE PROFESSIONALS
        • 3.3.2.4     LACK OF STANDARDIZATION OF LIQUID BIOPSY TESTS
        • 3.3.2.5     REGULATORY ISSUES
    • 3.4     REGULATORY AFFAIRS
      • 3.4.1     U.S.
      • 3.4.2     EUROPE
      • 3.4.3     CHINA
      • 3.4.4     INDIA
      • 3.4.5     JAPAN
    • 3.5     PORTER’S FIVE FORCE ANALYSIS
      • 3.5.1     THREAT OF NEW ENTRANTS
      • 3.5.2     THREAT OF SUBSTITUTES
      • 3.5.3     COMPETITIVE RIVALRY
      • 3.5.4     BARGAINING POWER OF SUPPLIERS
      • 3.5.5     BARGAINING POWER OF BUYERS
    • 3.6     PATENT TRENDS
    • 3.7     MARKET SHARE ANALYSIS
    • 3.8     REIMBURSEMENT SCENARIO
    • 3.9     CLINICAL TRIALS
    • 3.10     TECHNOLOGICAL ADVANCEMENTS
      • 3.10.1     MICRORNA (MIRNA)
      • 3.10.2     PROTEIN BIOMARKERS
      • 3.10.3     CIRCULATING MRNA
      • 3.10.4     CRISPR PAPER TEST (SHERLOCK)
    • 3.11     UPCOMING TESTS
    • 3.12     RESEARCH USE ONLY CELL-FREE DNA TESTS
    • 3.13     FUNDING SCENARIO
    • 3.14     LIQUID BIOPSY COMPANY COMPARISON BY APPLICATIONS
  • 4     MARKET SIZING
    • 4.1     U.S.LIQUID BIOPSY MARKET SIZING INFORMATION
      • 4.1.1     ONCOLOGY TESTING
        • 4.1.1.1     EARLY SCREENING
        • 4.1.1.2     COMPANION DIAGNOSTICS
        • 4.1.1.3     PROGNOSIS MONITORING
        • 4.1.1.4     RECURRENCE MONITORING
      • 4.1.2     NON-INVASIVE PRENATAL SCREENING (NIPT)
      • 4.1.3     TRANSPLANTATION DIAGNOSTICS
  • 5     LIQUID BIOPSY GLOBAL MARKET, BY BIOMARKER
    • 5.1     INTRODUCTION
    • 5.2     CIRCULATING TUMOUR CELLS (CTC)
    • 5.3     CELL-FREE DNA (CFDNA)
    • 5.4     EXOSOMES & OTHERS
  • 6     LIQUID BIOPSY GLOBAL MARKET, BY APPLICATION
    • 6.1     INTRODUCTION
    • 6.2     ONCOLOGY TESTING
      • 6.2.1     CANCER TYPES
        • 6.2.1.1     INTRODUCTION
        • 6.2.1.2     LUNG CANCER
        • 6.2.1.3     BREAST CANCER
        • 6.2.1.4     COLORECTAL CANCER
        • 6.2.1.5     MELANOMA
        • 6.2.1.6     PROSTATE CANCER
        • 6.2.1.7     OVARIAN CANCER
        • 6.2.1.8     OTHERS
      • 6.2.2     CANCER CARE
        • 6.2.2.1     INTRODUCTION
        • 6.2.2.2     EARLY SCREENING
        • 6.2.2.3     COMPANION DIAGNOSIS
        • 6.2.2.4     PROGNOSIS MONITORING
        • 6.2.2.5     RECURRENCE MONITORING
    • 6.3     PRENATAL TESTING
    • 6.4     TRANSPLANTATION
  • 7     LIQUID BIOPSY GLOBAL MARKET, BY SAMPLE
    • 7.1     INTRODUCTION
    • 7.2     BLOOD
    • 7.3     URINE AND OTHERS
  • 8     LIQUID BIOPSY GLOBAL MARKET, BY END-USERS
    • 8.1     INTRODUCTION
    • 8.2     HOSPITALS
    • 8.3     ACADEMIC & RESEARCH INSTITUTES
  • 9     REGIONAL ANALYSIS
    • 9.1     INTRODUCTION
    • 9.2     NORTH AMERICA
      • 9.2.1     UNITED STATES
      • 9.2.2     OTHERS
    • 9.3     EUROPE
      • 9.3.1     GERMANY
      • 9.3.2     FRANCE
      • 9.3.3     U.K.
      • 9.3.4     OTHERS
    • 9.4     ASIA-PACIFIC
      • 9.4.1     JAPAN
      • 9.4.2     CHINA
      • 9.4.3     INDIA
      • 9.4.4     OTHERS
    • 9.5     REST OF THE WORLD (ROW)
      • 9.5.1     BRAZIL
      • 9.5.2     REST OF LATIN AMERICA
      • 9.5.3     MIDDLE EAST & OTHERS
  • 10     COMPETITIVE LANDSCAPE
    • 10.1     INTRODUCTION
    • 10.2     AGREEMENTS
    • 10.3     COLLABORATIONS/PARTNERSHIPS
    • 10.4     NEW PRODUCT LAUNCHES
    • 10.5     APPROVALS
    • 10.6     ACQUISITIONS
    • 10.7     OTHERS
  • 11     MAJOR COMPANIES
    • 11.1     BGI (BGI DIAGNOSTICS)
      • 11.1.1     OVERVIEW
      • 11.1.2     FINANCIALS
      • 11.1.3     PRODUCTS NIFTY TEST
      • 11.1.4     KEY DEVELOPMENTS
      • 11.1.5     BUSINESS STRATEGY
      • 11.1.6     SWOT ANALYSIS
    • 11.2     BIOCEPT, INC.
      • 11.2.1     OVERVIEW
      • 11.2.2     FINANCIALS
      • 11.2.3     PRODUCT PORTFOLIO
      • 11.2.4     KEY DEVELOPMENTS
      • 11.2.5     BUSINESS STRATEGY
      • 11.2.6     SWOT ANALYSIS
    • 11.3     CAREDX, INC.
      • 11.3.1     OVERVIEW
      • 11.3.2     FINANCIALS
      • 11.3.3     PRODUCT DESCRIPTION
      • 11.3.4     KEY DEVELOPMENTS
      • 11.3.5     BUSINESS STRATEGY
      • 11.3.6     SWOT ANALYSIS
    • 11.4     CYNVENIO BIOSYSTEMS, INC
      • 11.4.1     OVERVIEW
      • 11.4.2     FINANCIALS
      • 11.4.3     PRODUCT PORTFOLIO
      • 11.4.4     KEY DEVELOPMENTS
      • 11.4.5     BUSINESS STRATEGY
      • 11.4.6     SWOT ANALYSIS
    • 11.5     EUROFINS SCIENTIFIC SE (LIFECODEXX)
      • 11.5.1     OVERVIEW
      • 11.5.2     FINANCIALS
      • 11.5.3     PRODUCT PORTFOLIO
      • 11.5.4     KEY DEVELOPMENTS
      • 11.5.5     BUSINESS STRATEGY
      • 11.5.6     SWOT ANALYSIS
    • 11.6     EXACT SCIENCES CORPORATION
      • 11.6.1     OVERVIEW
      • 11.6.2     FINANCIALS
      • 11.6.3     PRODUCT PORTFOLIO
      • 11.6.4     KEY DEVELOPMENTS
      • 11.6.5     BUSINESS STRATEGY
      • 11.6.6     SWOT ANALYSIS
    • 11.7     EXOSOME DIAGNOSTICS, INC
      • 11.7.1     OVERVIEW
      • 11.7.2     FINANCIALS
      • 11.7.3     PRODUCT PORTFOLIO
      • 11.7.4     KEY DEVELOPMENTS
      • 11.7.5     BUSINESS STRATEGY
      • 11.7.6     SWOT ANALYSIS
    • 11.8     GUARDANT HEALTH, INC.
      • 11.8.1     OVERVIEW
      • 11.8.2     FINANCIALS
      • 11.8.3     PRODUCT DESCRIPTION
      • 11.8.4     KEY DEVELOPMENTS
      • 11.8.5     BUSINESS STRATEGY
      • 11.8.6     SWOT ANALYSIS
    • 11.9     ILLUMINA, INC.
      • 11.9.1     OVERVIEW
      • 11.9.2     FINANCIALS
      • 11.9.3     PRODUCT PORTFOLIO
      • 11.9.4     KEY DEVELOPMENTS
      • 11.9.5     BUSINESS STRATEGY
      • 11.9.6     SWOT ANALYSIS
    • 11.10     IMMUCOR
      • 11.10.1     OVERVIEW
      • 11.10.2     FINANCIALS
      • 11.10.3     PRODUCT PORTFOLIO
      • 11.10.4     KEY DEVELOPMENTS
      • 11.10.5     BUSINESS STRATEGY
      • 11.10.6     SWOT ANALYSIS
    • 11.11     LABORATORY CORPORATION OF AMERICA HOLDINGS
      • 11.11.1     OVERVIEW
      • 11.11.2     FINANCIALS
      • 11.11.3     PRODUCT PORTFOLIO
      • 11.11.4     KEY DEVELOPMENTS
      • 11.11.5     BUSINESS STRATEGY
      • 11.11.6     SWOT ANALYSIS
    • 11.12     MDX HEALTH
      • 11.12.1     OVERVIEW
      • 11.12.2     FINANCIALS
      • 11.12.3     PRODUCT DESCRIPTION
      • 11.12.4     KEY DEVELOPMENTS
      • 11.12.5     BUSINESS STRATEGY
      • 11.12.6     SWOT ANALYSIS
    • 11.13     MYRIAD GENETICS, INC.
      • 11.13.1     OVERVIEW
      • 11.13.2     FINANCIALS
      • 11.13.3     PRODUCT PORTFOLIO
      • 11.13.4     KEY DEVELOPMENTS
      • 11.13.5     BUSINESS STRATEGY
      • 11.13.6     SWOT ANALYSIS
    • 11.14     NATERA, INC.
      • 11.14.1     OVERVIEW
      • 11.14.2     FINANCIALS
      • 11.14.3     PRODUCT PORTFOLIO
        • 11.14.3.1     PANORAMA
        • 11.14.3.2     CONSTELLATION
        • 11.14.3.3     SIGNATERA
        • 11.14.3.4     VISTARA
      • 11.14.4     KEY DEVELOPMENTS
      • 11.14.5     BUSINESS STRATEGY
      • 11.14.6     SWOT ANALYSIS
    • 11.15     ROCHE HOLDINGS AG
      • 11.15.1     OVERVIEW
      • 11.15.2     FINANCIALS
      • 11.15.3     PRODUCT DESCRIPTION
      • 11.15.4     KEY DEVELOPMENTS
      • 11.15.5     BUSINESS STRATEGY
      • 11.15.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     LIQUID BIOPSY GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
      • TABLE 2     LIQUID BIOPSY GLOBAL MARKET REVENUE, BY BIOMARKERS (2016-2024) ($MN)
      • TABLE 3     LIQUID BIOPSY GLOBAL MARKET REVENUE, BY APPLICATIONS, (2016-2024) ($MN)
      • TABLE 4     LIQUID BIOPSY GLOBAL MARKET REVENUE, BY SAMPLE (2016-2024) ($MN)
      • TABLE 5     LIQUID BIOPSY GLOBAL MARKET REVENUE, BY END-USERS (2016-2024) ($MN)
      • TABLE 6     ONCOLOGY TESTING U.S. MARKET
      • TABLE 7     NIPT GLOBAL TOTAL ADDRESSABLE MARKET (TAM) (HIGH RISK PREGNANCIES) (2017)($MN)
      • TABLE 8     KIDNEY TRANSPLANTATION DIAGNOSTICS GLOBAL TOTAL ADDRESSABLE MARKET (TAM) (2017)($MN)
      • TABLE 9     HEART TRANSPLANTATION DIAGNOSTIS GLOBAL TOTAL ADDRESSABLE MARKET (TAM) (2017)($MN)
      • TABLE 10     LIQUID BIOPSY GLOBAL MARKET REVENUE, BY BIOMARKER (2016-2024) ($MN)
      • TABLE 11     CIRCULATING TUMOR CELLS GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
      • TABLE 12     CELL-FREE DNA GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
      • TABLE 13     EXOSOMES & OTHERS GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
      • TABLE 14     LIQUID BIOPSY GLOBAL MARKET REVENUE, BY APPLICATIONS (2016-2024) ($MN)
      • TABLE 15     ONCOLOGY TESTING GLOBAL MARKET REVENUE, BY CANCER TYPE (2016-2024) ($MN)
      • TABLE 16     ONCOLOGY TESTING GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
      • TABLE 17     LUNG CANCER GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
      • TABLE 18     BREAST CANCER GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
      • TABLE 19     COLORECTAL CANCER GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
      • TABLE 20     MELANOMA GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
      • TABLE 21     PROSTATE CANCER GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
      • TABLE 22     OVARIAN CANCER GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
      • TABLE 23     OTHERS GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
      • TABLE 24     ONCOLOGY TESTING GLOBAL MARKET REVENUE, BY CANCER CARE (2016-2024) ($MN)
      • TABLE 25     EARLY SCREENING GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
      • TABLE 26     COMPANION DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
      • TABLE 27     PROGNOSIS GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
      • TABLE 28     RECURRENCE MONITORING GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
      • TABLE 29     PRENATAL (NIPT) TESTING GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
      • TABLE 30     TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
      • TABLE 31     LIQUID BIOPSY GLOBAL MARKET REVENUE, BY SAMPLE (2016-2024) ($MN)
      • TABLE 32     BLOOD SAMPLE GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
      • TABLE 33     URINE & OTHER SAMPLES GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
      • TABLE 34     LIQUID BIOPSY GLOBAL MARKET REVENUE, BY END-USERS,(2016-2024) ($MN)
      • TABLE 35     HOSPITALS GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
      • TABLE 36     ACADEMIC & RESEARCH INSTITUTES GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
      • TABLE 37     LIQUID BIOPSY GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
      • TABLE 38     NORTH AMERICA LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2016-2024) ($MN)
      • TABLE 39     NORTH AMERICA LIQUID BIOPSY MARKET REVENUE, BY APPLICATION (2016-2024) ($MN)
      • TABLE 40     NORTH AMERICA ONCOLOGY TESTING MARKET REVENUE, BY CANCER CARE (2016-2024) ($MN)
      • TABLE 41     NORTH AMERICA ONCOLOGY TESTING MARKET REVENUE, BY CANCER TYPE (2016-2024) ($MN)
      • TABLE 42     NORTH AMERCA LIQUID BIOPSY MARKET REVENUE, BY SAMPLE (2016-2024) ($MN)
      • TABLE 43     NORTH AMERICA LIQUID BIOPSY MARKET REVENUE, BY END-USERS, (2016-2024) ($MN)
      • TABLE 44     NORTH AMERICA LIQUID BIOPSY MARKET REVENUE, BY COUNTRY, (2016-2024) ($MN)
      • TABLE 45     EUROPE LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2016-2024) ($MN)
      • TABLE 46     EUROPE LIQUID BIOPSY MARKET REVENUE, BY APPLICATION (2016-2024) ($MN)
      • TABLE 47     EUROPE ONCOLOGY TESTING MARKET REVENUE, BY CANCER CARE (2016-2024) ($MN)
      • TABLE 48     EUROPE ONCOLOGY TESTING MARKET REVENUE, BY CANCER TYPE (2016-2024) ($MN)
      • TABLE 49     EUROPE LIQUID BIOPSY MARKET REVENUE, BY SAMPLE (2016-2024) ($MN)
      • TABLE 50     EUROPE LIQUID BIOPSY MARKET REVENUE, BY END-USERS, (2016-2024) ($MN)
      • TABLE 51     EUROPE LIQUID BIOPSY MARKET REVENUE, BY COUNTRY, (2016-2024) ($MN)
      • TABLE 52     ASIA-PACIFIC LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2016-2024) ($MN)
      • TABLE 53     ASIA-PACIFIC LIQUID BIOPSY MARKET REVENUE, BY APPLICATION (2016-2024) ($MN)
      • TABLE 54     ASIA-PACIFIC ONCOLOGY TESTING MARKET REVENUE, BY CANCER CARE (2016-2024) ($MN)
      • TABLE 55     ASIA-PACIFIC ONCOLOGY TESTING MARKET REVENUE, BY CANCER TYPE (2016-2024) ($MN)
      • TABLE 56     ASIA-PACIFIC LIQUID BIOPSY MARKET REVENUE, BY SAMPLE (2016-2024) ($MN)
      • TABLE 57     ASIA-PACIFIC LIQUID BIOPSY MARKET REVENUE, BY END-USERS, (2016-2024) ($MN)
      • TABLE 58     ASIA-PACIFIC LIQUID BIOPSY MARKET REVENUE, BY COUNTRY, (2016-2024) ($MN)
      • TABLE 59     ROW LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2016-2024) ($MN)
      • TABLE 60     ROW LIQUID BIOPSY MARKET REVENUE, BY APPLICATION (2016-2024) ($MN)
      • TABLE 61     ROW ONCOLOGY TESTING MARKET REVENUE, BY CANCER CARE (2016-2024) ($MN)
      • TABLE 62     ROW ONCOLOGY TESTING MARKET REVENUE, BY CANCER TYPE (2016-2024) ($MN)
      • TABLE 63     ROW LIQUID BIOPSY MARKET REVENUE, BY SAMPLE (2016-2024) ($MN)
      • TABLE 64     ROW LIQUID BIOPSY MARKET REVENUE, BY END-USERS (2016-2024) ($MN)
      • TABLE 65     ROW LIQUID BIOPSY MARKET REVENUE, BY COUNTRY, (2016-2024) ($MN)
      • TABLE 66     AGREEMENTS (2016-2018)
      • TABLE 67     COLLABORATIONS/PARTNERSHIPS (2016-2018)
      • TABLE 68     NEW PRODUCT LAUNCH (2016-2018)
      • TABLE 69     APPROVALS (2016-2018)
      • TABLE 70     ACQUISITIONS (2016-2018)
      • TABLE 71     OTHERS (2016-2018)
      • TABLE 72     BIOCEPT, INC: TOTAL REVENUE AND R&D EXPENSES 2015-2017 ($MN)
      • TABLE 73     CAREDX, INC.: TOTAL REVENUE AND R&D EXPENSES (2015-2017) ($MN)
      • TABLE 74     CAREDX, INC.: TOTAL REVENUE, BY SEGMENTS (2015-2017) ($MN)
      • TABLE 75     CAREDX, INC.: TOTAL REVENUE, BY GEOGRAPHY (2015-2017) ($MN)
      • TABLE 76     EUROFINS SCIENTIFIC: TOTAL REVENUE AND R&D EXPENSES (2015-2017) ($MN)
      • TABLE 77     EUROFINS SCIENTIFIC: TOTAL REVENUE, BY GEOGRAPHY (2015-2017) ($MN)
      • TABLE 78     EXACT SCIENCES CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 79     ILLUMINA INC: TOTAL REVENUE AND R&D EXPENSES (2015-2017) ($MN)
      • TABLE 80     ILLUMINA INC: TOTAL REVENUE, BY SEGMENT, (2015-2017) ($MN)
      • TABLE 81     ILLUMINA INC: TOTAL REVENUE, BY GEOGRAPHY (2015-2017) ($MN)
      • TABLE 82     IMMUCOR INC.: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 83     IMMUCOR INC.: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 84     IMMUCOR INC.: TOTAL REVENUE, BY GEOGRAPHY (2014-2016) ($MN)
      • TABLE 85     LABCORP.: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 86     LABCORP.: TOTAL REVENUE, BY SEGMENT, (2015-2017) ($MN)
      • TABLE 87     LABCORP.: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN)
      • TABLE 88     MDXHEALTH: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 89     MYRAID GENETICS: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 90     MYRIAD GENETICS, INC.: TOTAL REVENUE, BY SEGMENTS,(2015-2017) ($MN)
      • TABLE 91     NATERA, INC.: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 92     NATERA, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN)
      • TABLE 93     ROCHE HOLDINGS AG: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 94     ROCHE HOLDINGS AG: TOTAL REVENUE BY SEGMENTS (2015-2017) ($MN)
      • TABLE 95     ROCHE HOLDINGS AG: DIAGNOSTICS REVENUE BY TYPES (2015-2017) ($MN)
      • TABLE 96     ROCHE HOLDINGS AG: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN)

      LIST OF FIGURES

      • FIGURE 1     LIQUID BIOPSY GLOBAL MARKET REVENUE & SHARE, BY GEOGRAPHY, (2016-2024) ($MN)
      • FIGURE 2     LIQUID BIOPSY GLOBAL MARKET: RESEARCH APPROACH
      • FIGURE 3     LIQUID BIOPSY GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     LIQUID BIOPSY GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     LIQUID BIOPSY GLOBAL MARKET: MARKET CRACKDOWN AND DATA TRIANGULATION
      • FIGURE 6     LIQUID BIOPSY GLOBAL MARKET: MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     LIQUID BIOPSY GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 9     LIQUID BIOPSY GLOBAL MARKET: PCT FILING BY MAJOR PLAYERS (2013-2017)
      • FIGURE 10     LIQUID BIOPSY MARKET SHARE ANALYSIS BY MAJOR PLAYERS (2017) (%)
      • FIGURE 11     NIPT MARKET SHARE ANALYSIS BY MAJOR PLAYERS (2017) (%)
      • FIGURE 12     U.S. LIQUID BIOPSY MARKET: TOTAL ADDRESSABLE MARKET (TAM) ($MN)
      • FIGURE 13     LIQUID BIOPSY GLOBAL MARKET REVENUE, BY BIOMARKER, (2017 VS 2024) ($MN)
      • FIGURE 14     CIRCULATING TUMOR CELLS GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN)
      • FIGURE 15     CELL-FREE DNA GLOBAL MARKET REVENUE, BY REGION (2017 VS 2024) ($MN)
      • FIGURE 16     EXOSOME & OTHERS DNA GLOBAL MARKET REVENUE, BY REGION (2017 VS 2024) ($MN)
      • FIGURE 17     LIQUID BIOPSY GLOBAL MARKET REVENUE, BY APPLICATION, (2017 VS 2024) ($MN)
      • FIGURE 18     ONCOLOGY TESTING GLOBAL MARKET SHARE, BY CANCER TYPE (2017) (%)
      • FIGURE 19     ONCOLOGY TESTING GLOBAL MARKET REVENUE, BY REGION (2017 VS 2024) ($MN)
      • FIGURE 20     LUNG CANCER GLOBAL MARKET REVENUE, BY REGION (2017 VS 2024) ($MN)
      • FIGURE 21     BREAST CANCER GLOBAL MARKET REVENUE, BY REGION (2017 VS 2024) ($MN)
      • FIGURE 22     COLORECTAL CANCER GLOBAL MARKET REVENUE, BY REGION (2017 VS 2024) ($MN)
      • FIGURE 23     MELANOMA GLOBAL MARKET REVENUE, BY REGION (2017 VS 2024) ($MN)
      • FIGURE 24     PROSTATE CANCER GLOBAL MARKET REVENUE, BY REGION (2017 VS 2024) ($MN)
      • FIGURE 25     OVARIAN CANCER GLOBAL MARKET REVENUE, BY REGION (2017 VS 2024) ($MN)
      • FIGURE 26     OTHERS GLOBAL MARKET REVENUE, BY REGION (2017 VS 2024) ($MN)
      • FIGURE 27     EARLY SCREENING GLOBAL MARKET REVENUE, BY REGION (2017 VS 2024) ($MN)
      • FIGURE 28     COMPANION DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2017 VS 2024) ($MN)
      • FIGURE 29     PROGNOSIS GLOBAL MARKET REVENUE, BY REGION (2017 VS 2024) ($MN)
      • FIGURE 30     RECURRENCE MONITORING GLOBAL MARKET REVENUE, BY REGION (2017 VS 2024) ($MN)
      • FIGURE 31     PRENATAL (NIPT) TESTING GLOBAL MARKET REVENUE,BY REGION (2017 VS 2024) ($MN)
      • FIGURE 32     TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2017 VS 2024) ($MN)
      • FIGURE 33     LIQUID BIOPSY GLOBAL MARKET REVENUE, BY SAMPLE, (2017 VS 2024) ($MN)
      • FIGURE 34     BLOOD SAMPLE GLOBAL MARKET REVENUE, BY REGION (2017 VS 2024) ($MN)
      • FIGURE 35     URINE & OTHER SAMPLES GLOBAL MARKET REVENUE, BY REGION (2017 VS 2024) ($MN)
      • FIGURE 36     LIQUID BIOPSY GLOBAL MARKET REVENUE, BY END-USERS, (2017 VS 2024) ($MN)
      • FIGURE 37     HOSPITALS GLOBAL MARKET REVENUE, BY REGION (2017 VS 2024) ($MN)
      • FIGURE 38     ACADEMIC & RESEARCH INSTITUTES GLOBAL MARKET REVENUE, BY REGION (2017 VS 2024) ($MN)
      • FIGURE 39     LIQUID BIOPSY GLOBAL MARKET REVENUE, BY GEOGRAPHY, (2016-2024) ($MN)
      • FIGURE 40     NORTH AMERICA LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2017 VS 2024) ($MN)
      • FIGURE 41     NORTH AMERICA LIQUID BIOPSY MARKET REVENUE, BY APPLICATION AND CANCER CARE (2017) ($MN)
      • FIGURE 42     NORTH AMERICA ONCOLOGY TESTING MARKET SHARE, BY CANCER TYPE (2017) (%) CAGR (%)
      • FIGURE 43     NORTH AMERICA LIQUID BIOPSY MARKET SHARE, BY SAMPLE (2017 VS 2024) (%)
      • FIGURE 44     NORTH AMERICA LIQUID BIOPSY MARKET SHARE, BY END-USERS (2017 VS 2024) (%)
      • FIGURE 45     NORTH AMERICA LIQUID BIOPSY MARKET REVENUE, BY COUNTRY (2017 VS 2024) ($MN)
      • FIGURE 46     UNITED STATES LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2017 VS 2024) ($MN)
      • FIGURE 47     U.S. LIQUID BIOPSY MARKET REVENUE, BY APPLICATION & TYPE (2017) ($MN)
      • FIGURE 48     U.S. LIQUID BIOPSY MARKET REVENUE, BY SAMPLE & BY END-USERS (2017 VS 2024) ($MN)
      • FIGURE 49     OTHER NORTH AMERICAN COUNTRIES LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2017 VS 2024) ($MN)
      • FIGURE 50     OTHER NORTH AMERICAN COUNTRIES LIQUID BIOPSY MARKET REVENUE, BY APPLICATION & CANCER TYPE (2017) ($MN)
      • FIGURE 51     OTHER NORTH AMERICAN COUNTRIES LIQUID BIOPSY MARKET REVENUE, BY SAMPLE & BY END-USERS (2017 VS 2024) ($MN)
      • FIGURE 52     EUROPE LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2017 VS 2024) ($MN)
      • FIGURE 53     EUROPE ONCOLOGY TESTING MARKET REVENUE, BY APPLICATION AND CANCER CARE (2017) ($MN)
      • FIGURE 54     EUROPE ONCOLOGY TESTING MARKET SHARE, BY CANCER TYPE (2017) (%)
      • FIGURE 55     EUROPE LIQUID BIOPSY MARKET SHARE, BY SAMPLE (2017 VS 2024) (%)
      • FIGURE 56     EUROPE LIQUID BIOPSY MARKET SHARE, BY END-USERS (2017 VS 2024) (%)
      • FIGURE 57     EUROPE LIQUID BIOPSY MARKET REVENUE, BY COUNTRY (2017 VS 2024) ($MN)
      • FIGURE 58     GERMANY LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2017 VS 2024) ($MN)
      • FIGURE 59     GERMANY LIQUID BIOPSY MARKET REVENUE, BY APPLICATION & CANCER TYPE (2017) ($MN)
      • FIGURE 60     GERMANY LIQUID BIOPSY MARKET REVENUE, BY SAMPLE & BY END-USERS (2017 VS 2024) ($MN)
      • FIGURE 61     FRANCE LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2017 VS 2024) ($MN)
      • FIGURE 62     FRANCE LIQUID BIOPSY MARKET REVENUE, BY APPLICATION & CANCER TYPE (2017) ($MN)
      • FIGURE 63     FRANCE LIQUID BIOPSY MARKET REVENUE, BY SAMPLE & BY END-USERS (2017 VS 2024) ($MN)
      • FIGURE 64     U.K. LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2017 VS 2024) ($MN)
      • FIGURE 65     U.K. LIQUID BIOPSY MARKET REVENUE, BY APPLICATION & CANCER TYPE (2017) ($MN)
      • FIGURE 66     U.K. LIQUID BIOPSY MARKET REVENUE, BY SAMPLE & BY END-USERS (2017 VS 2024) ($MN)
      • FIGURE 67     OTHER EUROPEAN COUNTRIES LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2017 VS 2024) ($MN)
      • FIGURE 68     OTHER EUROPEAN COUNTRIES LIQUID BIOPSY MARKET REVENUE, BY APPLICATION & CANCER TYPE (2017) ($MN)
      • FIGURE 69     OTHER EUROPEAN COUNTRIES LIQUID BIOPSY MARKET REVENUE, BY SAMPLE & BY END-USERS (2017 VS 2024) ($MN)
      • FIGURE 70     ASIA-PACIFIC LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2017 VS 2024) ($MN)
      • FIGURE 71     ASIA-PACIFIC LIQUID BIOPSY MARKET REVENUE, BY APPLICATION AND CANCER CARE (2017) ($MN)
      • FIGURE 72     ASIA-PACIFIC ONCOLOGY TESTING MARKET SHARE, BY CANCER TYPE (2017) (%)
      • FIGURE 73     ASIA-PACIFIC LIQUID BIOPSY MARKET SHARE, BY SAMPLE (2017 VS 2024) (%)
      • FIGURE 74     ASIA-PACIFIC LIQUID BIOPSY MARKET SHARE, BY END-USERS (2017 VS 2024) (%)
      • FIGURE 75     ASIA-PACIFIC LIQUID BIOPSY MARKET REVENUE, BY COUNTRY (2017 VS 2024) ($MN)
      • FIGURE 76     JAPAN LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2017 VS 2024) ($MN)
      • FIGURE 77     JAPAN LIQUID BIOPSY MARKET REVENUE, BY APPLICATION & TYPE (2017) ($MN)
      • FIGURE 78     JAPAN LIQUID BIOPSY MARKET REVENUE, BY SAMPLE & BY END-USERS (2017 VS 2024) ($MN)
      • FIGURE 79     CHINA LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2017 VS 2024) ($MN)
      • FIGURE 80     CHINA LIQUID BIOPSY MARKET REVENUE, BY APPLICATION & CANCER TYPE (2017) ($MN)
      • FIGURE 81     CHINA LIQUID BIOPSY MARKET REVENUE, BY SAMPLE & BY END-USERS (2017 VS 2024) ($MN)
      • FIGURE 82     INDIA LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2017 VS 2024) ($MN)
      • FIGURE 83     INDIA LIQUID BIOPSY MARKET REVENUE, BY APPLICATION & CANCER TYPE (2017) ($MN)
      • FIGURE 84     INDIA LIQUID BIOPSY MARKET REVENUE, BY SAMPLE & BY END-USERS (2017 VS 2024) ($MN)
      • FIGURE 85     OTHER APAC COUNTRIES LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2017 VS 2024) ($MN)
      • FIGURE 86     OTHER APAC COUNTRIES LIQUID BIOPSY MARKET REVENUE, BY APPLICATION & CANCER TYPE (2017) ($MN)
      • FIGURE 87     OTHER APAC COUNTRIES LIQUID BIOPSY MARKET REVENUE, BY SAMPLE & BY END-USERS (2017 VS 2024) ($MN)
      • FIGURE 88     ROW LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2017 VS 2024) ($MN)
      • FIGURE 89     ROW LIQUID BIOPSY MARKET REVENUE, BY APPLICATION AND CANCER CARE (2017) ($MN)
      • FIGURE 90     ROW ONCOLOGY TESTING MARKET SHARE, BY CANCER TYPE (2017) (%)
      • FIGURE 91     ROW LIQUID BIOPSY MARKET SHARE, BY SAMPLE (2017 VS 2024) (%)
      • FIGURE 92     ROW LIQUID BIOPSY MARKET SHARE, BY END-USERS (2017 VS 2024) (%)
      • FIGURE 93     ROW LIQUID BIOPSY MARKET REVENUE, BY COUNTRY (2017 VS 2024) ($MN)
      • FIGURE 94     BRAZIL LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2017 VS 2024) ($MN)
      • FIGURE 95     BRAZIL LIQUID BIOPSY MARKET REVENUE, BY APPLICATION & CANCER TYPE (2017) ($MN)
      • FIGURE 96     BRAZIL LIQUID BIOPSY MARKET REVENUE, BY SAMPLE & BY END-USERS (2017 VS 2024) ($MN)
      • FIGURE 97     REST OF LATIN AMERICA LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2017 VS 2024) ($MN)
      • FIGURE 98     REST OF LATIN AMERICA LIQUID BIOPSY MARKET REVENUE, BY APPLICATION & CANCER TYPE (2017) ($MN)
      • FIGURE 99     REST OF LATIN AMERICA LIQUID BIOPSY MARKET REVENUE, BY SAMPLE & BY END-USERS (2017 VS 2024) ($MN)
      • FIGURE 100     MIDDLE EAST & OTHERS LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2017 VS 2024) ($MN)
      • FIGURE 101     MIDDLE EAST & OTHERS LIQUID BIOPSY MARKET REVENUE, BY APPLICATION & CANCER TYPE (2017) ($MN)
      • FIGURE 102     MIDDLE EAST & OTHERS LIQUID BIOPSY MARKET REVENUE, BY SAMPLE & BY END-USERS (2017 VS 2024) ($MN)
      • FIGURE 103     KEY GROWTH STRATEGIES, (2016 – 2018)
      • FIGURE 104     SWOT: BGI
      • FIGURE 105     SWOT: BIOCEPT, INC.
      • FIGURE 106     SWOT: CAREDX, INC.
      • FIGURE 107     SWOT: CYNVENIO BIOSYSTEMS, INC.
      • FIGURE 108     SWOT: EUROFINS SCIENTIFIC SE
      • FIGURE 109     SWOT: EXACT SCIENCES CORPORATION
      • FIGURE 110     SWOT: EXOSOME DIAGNOSTICS
      • FIGURE 111     SWOT: GUARDANT HEALTH, INC.
      • FIGURE 112     SWOT: ILLUMINA, INC.
      • FIGURE 113     SWOT: IMMUCOR, INC.
      • FIGURE 114     SWOT: LABORATORY CORPORATION OF AMERICA HOLDINGS
      • FIGURE 115     SWOT: MDXHEALTH
      • FIGURE 116     SWOT: MYRIAD GENETICS
      • FIGURE 117     SWOT: NATERA, INC.
      • FIGURE 118     SWOT: ROCHE HOLDINGS AG

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     ABBOTT DIAGNOSTICS
      • 2     ACTORIUS INNOVATIONS & RESEARCH
      • 3     ADAPTIVE BIOTECHNOLOGIES
      • 4     ADMERA HEALTH
      • 5     AFFINITY DNA
      • 6     AGENA BIOSCIENCE, INC
      • 7     AGILENT (MULTIPLICOM)
      • 8     AIOCARE PVT LTD (NIPTLAB)
      • 9     AMBRY GENETICS
      • 10     ANNOROAD GENE TECHNOLOGY
      • 11     ANPAC TECHNOLOGY USA (ANPAC BIO)
      • 12     APOLLO CENTER FOR FETAL MEDICINE
      • 13     ARUP LABORATORIES
      • 14     BEIJING BERRY AND KANG BIOTECHNOLOGY CO., LTD (BERRY GENOMICS)
      • 15     BGI DIAGNOSTICS
      • 16     BIOARRAY SL
      • 17     BIOCARTIS N.V.
      • 18     BIOCEPT, INC
      • 19     BIODESIX, INC
      • 20     BIOFLUIDICA
      • 21     BIOMARCARE TECHNOLOGIES
      • 22     BIO-RAD LABORATORIES,
      • 23     BOREAL GENOMICS
      • 24     CANCER GENETICS, INC
      • 25     CAREDX, INC
      • 26     CELLMAX LIFE
      • 27     CHRONIX BIOMEDICAL
      • 28     CIRCULOGENE THERANOSTICS
      • 29     COOPER GENOMICS (RECOMBINE)
      • 30     COUNSYL, INC
      • 31     CREATV MICROTECH, INC
      • 32     CYNVENIO BIOSYSTEMS, INC
      • 33     DATAR GENETICS LIMITED
      • 34     DIACARTA, INC
      • 35     DIADX
      • 36     DNA FORENSICS LABORATORY
      • 37     DNA LABS INDIA
      • 38     EONE-DIAGNOMICS GENOME CENTER (EDGC)
      • 39     EPIC SCIENCES, INC
      • 40     EPIGENOMICS AG
      • 41     EUROFINS SCIENTIFIC SE
      • 42     EXACT SCIENCES CORPORATION
      • 43     EXOSOME DIAGNOSTICS, INC
      • 44     FOUNDATION MEDICINE, INC
      • 45     FUTURE HEALTH BIOBANK
      • 46     GATC BIOTECH AG
      • 47     GENEPATH DX
      • 48     GENETECH
      • 49     GENETRACER BIOTECH
      • 50     GENOME CARE
      • 51     GENOMIC DIAGNOSTICS
      • 52     GENOMIC HEALTH, INC
      • 53     GENOPTIX
      • 54     GENSIGNIA LIFE SCIENCES, INC.
      • 55     GUARDANT HEALTH, INC
      • 56     IGENOMIX
      • 57     ILLUMINA, INC
      • 58     IMMUCOR
      • 59     IMPACTLAB SRL
      • 60     INDIVUMED GMBH
      • 61     INIVATA LIMITED
      • 62     INTEGRATED DIAGNOSTICS, INC. (INDI DX)
      • 63     INVITAE CORPORATION
      • 64     LABCORP
      • 65     LABGENOMICS
      • 66     LABORATORY OF ADVANCED MEDICINE (IVYGENELABS)
      • 67     LCM GENECT SRL
      • 68     LIFECELL INTERNATIONAL PVT. LTD
      • 69     LIQUID BIOTECH USA, INC
      • 70     LUCENCE DIAGNOSTICS PTE LTD
      • 71     MAPMYGENOME
      • 72     MDNA LIFESCIENCES
      • 73     MDX HEALTH
      • 74     MEDGENOME LABS PVT. LTD
      • 75     MENARINI SILICON BIOSYSTEMS
      • 76     METAMARK GENETICS, INC.
      • 77     MICROGENOMICS SRL
      • 78     MIRXES PTE LTD
      • 79     MOLECULAR MD
      • 80     MYRIAD GENETICS, INC
      • 81     NATERA, INC
      • 82     NEOGENOMICS LABORATORIES, INC
      • 83     NIPD GENETICS PUBLIC COMPANY LTD
      • 84     NUCLEIX
      • 85     NXGEN MDX LLC
      • 86     ONCOCYTE CORPORATION
      • 87     ONCODNA S.A.
      • 88     OPKO HEALTH, INC (BIO-REFERENCE LABORATORIES) (GENPATH DIAGNOSTICS) (GENEDX)
      • 89     PANAGENE
      • 90     PANGAEA ONCOLOGY
      • 91     PATHWAY GENOMICS
      • 92     PERSONAL GENOME DIAGNOSTICS, INC
      • 93     PGL LABS, LLC (PERSONALIZED GENOMICS)
      • 94     POSITIVE BIOSCIENCE
      • 95     PRECIPIODX
      • 96     PREDICINE, INC.
      • 97     PREMAITHA HEALTH, PLC
      • 98     PROGENITY, INC
      • 99     PROVISTA DIAGNOSTICS, INC
      • 100     PROXEOM
      • 101     QIAGEN N.V.
      • 102     QUEST DIAGNOSTICS INCORPORATED
      • 103     RESOLUTION BIOSCIENCES, INC
      • 104     RGCC GROUP
      • 105     ROCHE DIAGNOSTICS
      • 106     SAGA DIAGNOSTICS
      • 107     SHANGHAI GENOMATRIX MEDICAL LABORATORY CO. LTD.
      • 108     SIEMENS (NEO NEW ONCOLOGY GMBH)
      • 109     SISTEMAS GENOMICOS SL
      • 110     STRAND LIFE SCIENCES PVT LTD
      • 111     SYNAPSEDIAGNOSTICS
      • 112     SYNLAB INTERNATIONAL
      • 113     SYSMEX INOSTICS GMBH
      • 114     TAI DIAGNOSTICS
      • 115     TROVAGENE, INC
      • 116     VANADIS DIAGNOSTICS (PERKIN ELMER)
      • 117     VARIANTYX
      • 118     VERMILLION, INC (ASPIRA LABS)
      • 119     VICTORIAN CLINICAL GENETICS SERVICES (VCGS)
      • 120     VOLITIONRX LIMITED
      • 121     ZER LABORATORIES, LTD